Tasly Pharmaceutical Group Co., Ltd reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 4,357.68 million compared to CNY 3,992.3 million a year ago. Revenue was CNY 4,392 million compared to CNY 4,033.76 million a year ago.

Net income was CNY 707.1 million compared to net loss of CNY 416.55 million a year ago. Basic earnings per share from continuing operations was CNY 0.4715 compared to basic loss per share from continuing operations of CNY 0.2783 a year ago. Diluted earnings per share from continuing operations was CNY 0.4715 compared to diluted loss per share from continuing operations of CNY 0.2783 a year ago.